[Ip-health] EP Development committee ACTA vote on 14 May

Gaelle Krikorian gaelle.krikorian at gmail.com
Sat May 5 07:09:32 PDT 2012


it's development in the sense of human dev.
the ITRE committee is the one more business oriented.

gk

Le 4 mai 2012 à 10:29, Mohga Kamal-Yanni a écrit :

> Is this the committee that is meant to look after development issues as in 
> human development or the development of big companies?
> 
> 
> Best wishes 
> ___________________________________
> Mohga - 
> Dr. Mohga M Kamal-Yanni
> Senior health & HIV policy advisor
> Oxfam GB
> John Smith Drive, Oxford, OX4 2 JY
> Tel               +44(0) 1865 472290
> UK Mobile   + 44 (0)777 62 55 884
> Skype    Mohga Kamal-Yanni
> 
> 
> 
> From:   Ante <ante at ffii.org>
> To:     ip-health at lists.keionline.org
> Date:   04/05/2012 09:00
> Subject:        [Ip-health] EP Development committee ACTA vote on 14 May
> Sent by:        ip-health-bounces at lists.keionline.org
> 
> 
> 
> EP Development committee ACTA vote on 14 May
> http://acta.ffii.org/?p=1306
> with links
> 
> May 3, 2012
> By Ante
> 
> May 14th, the European Parliament Development committee (DEVE) will vote 
> on 
> ACTA. (Agenda, point 13) The committee?s ACTA rapporteur, Mr Zahradil, 
> wrote a 
> new version of his draft opinion. The draft calls on the Committee on 
> International Trade, as the committee responsible, to propose that 
> Parliament 
> give its consent.
> 
> Non of the serious objections against ACTA made the draft opinion. See for 
> 
> instance our 23th Januari letter to the DEVE committee and KEI: What?s 
> (still) 
> wrong with ACTA, and why governments should reject the illegitimate 
> agreement.
> 
> The deadline for amendments (consent or rejection) is set for the 8th May 
> at 
> noon.
> 
> The draft:
> 
> 2011/0167 (NLE)
> 25/04/2012
> DRAFT OPINION
> of the Committee on Development
> for the Committee on International Trade
> 
> on the proposal for a Council decision on the conclusion of the Anti-
> Counterfeiting Trade Agreement between the European Union and its Member 
> States, Australia, Canada, Japan, the Republic of Korea, the United 
> Mexican 
> States, the Kingdom of Morocco, New Zealand, the Republic of Singapore, 
> the 
> Swiss Confederation and the United States of America
> 
> (COM(2011)0380 ? C7?0027/2012 ? 2011/0167(NLE))
> Rapporteur: Jan Zahradil
> PA_Leg_Consent
> 
> SHORT JUSTIFICATION
> 
> The defence of intellectual property rights and active combating of 
> counterfeiting are essential for development, as protection of 
> intellectual 
> property safeguards and encourages creation, innovation and 
> entrepreneurship, 
> makes it possible for a business to grow and creates wealth.
> 
> The conclusion of negotiations on the Anti-Counterfeiting Trade Agreement 
> (ACTA) provides a WTO-plus legal framework in addition to the TRIPS 
> Agreement, 
> against counterfeiting, piracy and a broad range of IPR infringements by 
> establishing common rules on civil and criminal enforcement and on customs 
> 
> procedures for ACTA Parties1.
> 
> Furthermore ACTA membership is not exclusive and additional Parties, 
> including 
> developing and emerging countries, may join, thus promoting widespread IPR 
> 
> protection and enhancing the fight against counterfeiting and piracy 
> worldwide. In the future, ACTA could potentially attain a multilateral 
> level 
> as part of the WTO or WIPO (World Intellectual Property Organization).
> 
> Furthermore the Commission made a public commitment not to impose ACTA 
> provisions on third countries through their incorporation in free trade 
> agreements and Economic Partnership Agreements.
> 
> The Commission has ensured that ACTA provisions comply with the Union 
> acquis 
> and that nothing in ACTA contradicts the obligations between parties under 
> 
> existing agreements, including the TRIPS Agreement2.
> 
> Legitimate trade in generic medicines is essential to the development of 
> public health worldwide, and especially in developing countries. The 
> Committee 
> appreciates the unequivocal language of ACTA provisions which safeguard 
> access 
> to public health and recognises the principles enshrined in the Doha 
> Declaration on the TRIPS Agreement and Public Health3.
> 
> The Commission in its written answer on ACTA and access to medicine4, 
> stated 
> that ACTA will not serve as a basis to interfere with access to medicine 
> and, 
> in particular with trade in generic medicines, and that there will be no 
> obligation to apply border controls and criminal enforcement provisions to 
> 
> suspected patent infringements on medicines for countries dependent on 
> imported pharmaceuticals.
> 
> ******
> The Committee on Development calls on the Committee on International 
> Trade, as 
> the committee responsible, to propose that Parliament give its consent.
> 
> 1 ACTA negotiations were concluded on 15 November 2010 and the initialling 
> 
> took place on 25 November 2010 after 11 rounds of negotiations between 
> Australia, Canada, the EU, Japan, South-Korea, Mexico, Morocco, New 
> Zealand, 
> Singapore, Switzerland and the USA.
> 
> 2 See also Article 1in Section 1 of Chapter I of ACTA.
> 
> 3 The Doha Declaration on the TRIPS Agreement and Public Health was 
> adopted on 
> 14 November 2001 at the Fourth WTO Ministerial Conference;
> 
> 4 Commissioner De Gucht, written answer to the European Parliament, 
> P-9346/10 
> EN, (14.12.2010)
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
> 
> 
> 
> 
> Oxfam works with others to overcome poverty and suffering.
> 
> Oxfam GB is a member of Oxfam International and a company limited by guarantee registered in England No. 612172.
> Registered office: Oxfam House, John Smith Drive, Cowley, Oxford, OX4 2JY.
> A registered charity in England and Wales (no 202918) and Scotland (SC 039042)
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

----------------------
Gaelle Krikorian
galk at free.fr

Tel +33 (0)6 09 17 70 55









More information about the Ip-health mailing list